_id
690f3d8bccc777a4e85d1ab5
Ticker
CERS
Name
Cerus Corporation
Exchange
NASDAQ
Address
1220 Concord Avenue, Concord, CA, United States, 94520
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://www.cerus.com
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Last Close
2.15
Volume
658057
Current Price
2.215
Change
3.0232558139534857
Last Updated
2025-11-29T11:19:47.617Z
Image
data:image/webp;base64,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
Ipo Date
1997-01-30T00:00:00.000Z
Market Cap
338074016
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9475
Sentiment Sources
2
Rating
4.6
Target Price
4.6667
Strong Buy
4
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
52698000
Cost Of Revenue
24558000
Gross Profit
28140000
Operating Expenses
26904000
Operating Income
1236000
Interest Expense
2119000
Pretax Income
65000
Net Income
-19000
Eps
-0.00009904603033936298
Dividends Per Share
-
Shares Outstanding
192087501
Income Tax Expense
85000
EBITDA
2566000
Operating Margin
2.3454400546510303
Total Other Income Expense Net
-1171000
Cash
15670000
Short Term Investments
62842000
Receivables
29772000
Inventories
53139000
Total Current Assets
167127000
Property Plant Equipment
14665000
Total Assets
215185000
Payables
25468000
Short Term Debt
38862000
Long Term Debt
48655000
Total Liabilities
152981000
Equity
61463000
Depreciation
382000
Change In Working Capital
-4313000
Cash From Operations
1927000
Capital Expenditures
1833000
Cash From Investing
-2509000
Cash From Financing
320000
Net Change In Cash
-321000
PE
-
PB
6.101681499438687
ROE
-0.030912906952150074
ROA
-0.008829611729442109
FCF
94000
Fcf Percent
0.0017837489088769972
Piotroski FScore
2
Health Score
12
Deep Value Investing Score
3.5
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
52698000
Quarters > 0 > income Statement > cost Of Revenue
24558000
Quarters > 0 > income Statement > gross Profit
28140000
Quarters > 0 > income Statement > operating Expenses
26904000
Quarters > 0 > income Statement > operating Income
1236000
Quarters > 0 > income Statement > interest Expense
2119000
Quarters > 0 > income Statement > pretax Income
65000
Quarters > 0 > income Statement > net Income
-19000
Quarters > 0 > income Statement > eps
-0.00009904603033936298
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
191830000
Quarters > 0 > income Statement > income Tax Expense
85000
Quarters > 0 > income Statement > EBITDA
2566000
Quarters > 0 > income Statement > operating Margin
2.3454400546510303
Quarters > 0 > income Statement > total Other Income Expense Net
-1171000
Quarters > 0 > balance Sheet > cash
15670000
Quarters > 0 > balance Sheet > short Term Investments
62842000
Quarters > 0 > balance Sheet > receivables
29772000
Quarters > 0 > balance Sheet > inventories
53139000
Quarters > 0 > balance Sheet > total Current Assets
167127000
Quarters > 0 > balance Sheet > property Plant Equipment
14665000
Quarters > 0 > balance Sheet > total Assets
215185000
Quarters > 0 > balance Sheet > payables
25468000
Quarters > 0 > balance Sheet > short Term Debt
38862000
Quarters > 0 > balance Sheet > long Term Debt
48655000
Quarters > 0 > balance Sheet > total Liabilities
152981000
Quarters > 0 > balance Sheet > equity
61463000
Quarters > 0 > cash Flow > net Income
-19000
Quarters > 0 > cash Flow > depreciation
382000
Quarters > 0 > cash Flow > change In Working Capital
-4313000
Quarters > 0 > cash Flow > cash From Operations
1927000
Quarters > 0 > cash Flow > capital Expenditures
1833000
Quarters > 0 > cash Flow > cash From Investing
-2509000
Quarters > 0 > cash Flow > cash From Financing
320000
Quarters > 0 > cash Flow > net Change In Cash
-321000
Quarters > 0 > ratios > PE
-0.00009904603033936298
Quarters > 0 > ratios > PB
6.101681499438687
Quarters > 0 > ratios > ROE
-0.030912906952150074
Quarters > 0 > ratios > ROA
-0.008829611729442109
Quarters > 0 > ratios > FCF
94000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.0017837489088769972
Quarters > 0 > health Score
12
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
52445000
Quarters > 1 > income Statement > cost Of Revenue
23470000
Quarters > 1 > income Statement > gross Profit
28975000
Quarters > 1 > income Statement > operating Expenses
32398000
Quarters > 1 > income Statement > operating Income
-3423000
Quarters > 1 > income Statement > interest Expense
2150000
Quarters > 1 > income Statement > pretax Income
-5639000
Quarters > 1 > income Statement > net Income
-5707000
Quarters > 1 > income Statement > eps
-0.029832567524477133
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
191301000
Quarters > 1 > income Statement > income Tax Expense
76000
Quarters > 1 > income Statement > EBITDA
-3145000
Quarters > 1 > income Statement > operating Margin
-6.526837639431786
Quarters > 1 > income Statement > total Other Income Expense Net
-2216000
Quarters > 1 > balance Sheet > cash
15991000
Quarters > 1 > balance Sheet > short Term Investments
62034000
Quarters > 1 > balance Sheet > receivables
31394000
Quarters > 1 > balance Sheet > inventories
54529000
Quarters > 1 > balance Sheet > total Current Assets
168534000
Quarters > 1 > balance Sheet > property Plant Equipment
15556000
Quarters > 1 > balance Sheet > total Assets
213071000
Quarters > 1 > balance Sheet > payables
30518000
Quarters > 1 > balance Sheet > short Term Debt
30729000
Quarters > 1 > balance Sheet > long Term Debt
56766000
Quarters > 1 > balance Sheet > total Liabilities
156901000
Quarters > 1 > balance Sheet > equity
55428000
Quarters > 1 > cash Flow > net Income
-5715000
Quarters > 1 > cash Flow > depreciation
344000
Quarters > 1 > cash Flow > change In Working Capital
-3417000
Quarters > 1 > cash Flow > cash From Operations
-2446000
Quarters > 1 > cash Flow > capital Expenditures
477000
Quarters > 1 > cash Flow > cash From Investing
-1089000
Quarters > 1 > cash Flow > cash From Financing
-129000
Quarters > 1 > cash Flow > net Change In Cash
-3454000
Quarters > 1 > ratios > PE
-0.029832567524477133
Quarters > 1 > ratios > PB
6.747374161073825
Quarters > 1 > ratios > ROE
-10.296240167424406
Quarters > 1 > ratios > ROA
-2.6784499063692384
Quarters > 1 > ratios > FCF
-2923000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.0557345790828487
Quarters > 1 > health Score
13
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
43239000
Quarters > 2 > income Statement > cost Of Revenue
17815000
Quarters > 2 > income Statement > gross Profit
25424000
Quarters > 2 > income Statement > operating Expenses
31277000
Quarters > 2 > income Statement > operating Income
-5853000
Quarters > 2 > income Statement > interest Expense
2110000
Quarters > 2 > income Statement > pretax Income
-7644000
Quarters > 2 > income Statement > net Income
-7717000
Quarters > 2 > income Statement > eps
-0.04125281986037014
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
187066000
Quarters > 2 > income Statement > income Tax Expense
74000
Quarters > 2 > income Statement > EBITDA
-5227000
Quarters > 2 > income Statement > operating Margin
-13.536390758343162
Quarters > 2 > income Statement > total Other Income Expense Net
-1791000
Quarters > 2 > balance Sheet > cash
19476000
Quarters > 2 > balance Sheet > short Term Investments
61443000
Quarters > 2 > balance Sheet > receivables
26344000
Quarters > 2 > balance Sheet > inventories
48161000
Quarters > 2 > balance Sheet > total Current Assets
161515000
Quarters > 2 > balance Sheet > property Plant Equipment
16148000
Quarters > 2 > balance Sheet > total Assets
206776000
Quarters > 2 > balance Sheet > payables
27677000
Quarters > 2 > balance Sheet > short Term Debt
22629000
Quarters > 2 > balance Sheet > long Term Debt
64876000
Quarters > 2 > balance Sheet > total Liabilities
150534000
Quarters > 2 > balance Sheet > equity
55492000
Quarters > 2 > cash Flow > net Income
-7718000
Quarters > 2 > cash Flow > depreciation
307000
Quarters > 2 > cash Flow > change In Working Capital
-1322000
Quarters > 2 > cash Flow > cash From Operations
-844000
Quarters > 2 > cash Flow > capital Expenditures
112000
Quarters > 2 > cash Flow > cash From Investing
-1189000
Quarters > 2 > cash Flow > cash From Financing
1071000
Quarters > 2 > cash Flow > net Change In Cash
-776000
Quarters > 2 > ratios > PE
-0.04125281986037014
Quarters > 2 > ratios > PB
6.590391948388957
Quarters > 2 > ratios > ROE
-13.906509046349022
Quarters > 2 > ratios > ROA
-3.7320578790575305
Quarters > 2 > ratios > FCF
-956000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.022109669511320797
Quarters > 2 > health Score
13
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
50809000
Quarters > 3 > income Statement > cost Of Revenue
23424000
Quarters > 3 > income Statement > gross Profit
27385000
Quarters > 3 > income Statement > operating Expenses
28834000
Quarters > 3 > income Statement > operating Income
-1449000
Quarters > 3 > income Statement > interest Expense
2053000
Quarters > 3 > income Statement > pretax Income
-2451000
Quarters > 3 > income Statement > net Income
-2521000
Quarters > 3 > income Statement > eps
-0.013659292490910963
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
184563000
Quarters > 3 > income Statement > income Tax Expense
111000
Quarters > 3 > income Statement > EBITDA
-66000
Quarters > 3 > income Statement > operating Margin
-2.851856954476569
Quarters > 3 > income Statement > total Other Income Expense Net
-1002000
Quarters > 3 > balance Sheet > cash
20266000
Quarters > 3 > balance Sheet > short Term Investments
60186000
Quarters > 3 > balance Sheet > receivables
29777000
Quarters > 3 > balance Sheet > inventories
38150000
Quarters > 3 > balance Sheet > total Current Assets
152022000
Quarters > 3 > balance Sheet > property Plant Equipment
15538000
Quarters > 3 > balance Sheet > total Assets
200917000
Quarters > 3 > balance Sheet > payables
21695000
Quarters > 3 > balance Sheet > short Term Debt
21572000
Quarters > 3 > balance Sheet > long Term Debt
64862000
Quarters > 3 > balance Sheet > total Liabilities
144021000
Quarters > 3 > balance Sheet > equity
56145000
Quarters > 3 > cash Flow > net Income
-2562000
Quarters > 3 > cash Flow > depreciation
332000
Quarters > 3 > cash Flow > change In Working Capital
1162000
Quarters > 3 > cash Flow > cash From Operations
4929000
Quarters > 3 > cash Flow > capital Expenditures
976000
Quarters > 3 > cash Flow > cash From Investing
-7286000
Quarters > 3 > cash Flow > cash From Financing
746000
Quarters > 3 > cash Flow > net Change In Cash
-1848000
Quarters > 3 > ratios > PE
-0.013659292490910963
Quarters > 3 > ratios > PB
6.426585893668181
Quarters > 3 > ratios > ROE
-4.49015940867397
Quarters > 3 > ratios > ROA
-1.2547469850734383
Quarters > 3 > ratios > FCF
3953000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.07780117695683836
Quarters > 3 > health Score
20
Valuation > metrics > PE
-0.00009904603033936298
Valuation > metrics > PB
6.101681499438687
Valuation > final Score
20
Valuation > verdict
103.4% Overvalued
Profitability > metrics > ROE
-0.030912906952150074
Profitability > metrics > ROA
-0.011368599927001621
Profitability > metrics > Net Margin
-0.0003605449922198186
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.488993378129932
Risk > metrics > Interest Coverage
0.58329400660689
Risk > final Score
20
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.597963625058293
Liquidity > metrics > Quick Ratio
1.7719260065288356
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
12
Prev Risks > 1
7
Prev Risks > 2
15
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-12T15:07:27.381Z
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAnalyst Downgrade: Will PHGE stock deliver long term returns - 2025 Support & Resistance & Risk Controlled Daily Trade Plans moha.gov.vn
Read more →Cerus (Nasdaq: CERS) inks BCA deal to expand INTERCEPT blood safety tech access - Stock Titan
12/10/2025
Cerus (Nasdaq: CERS) inks BCA deal to expand INTERCEPT blood safety tech access Stock Titan
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$4.6667
Analyst Picks
Strong Buy
4
Buy
0
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 100.71% of the total shares of Cerus Corporation
1.
BlackRock Inc(10.8136%)
since
2025/06/30
2.
ARK Investment Management LLC(10.0197%)
since
2025/06/30
3.
Baker Bros Advisors LP(6.7209%)
since
2025/06/30
4.
Vanguard Group Inc(5.5928%)
since
2025/06/30
5.
ARK Disruptive Innovation Full Composite(5.5401%)
since
2025/06/30
6.
ARK Innovation ETF(5.457%)
since
2025/08/28
7.
Wasatch Advisors LP(4.4516%)
since
2025/06/30
8.
Wasatch Ultra Growth(4.0237%)
since
2025/06/30
9.
ARK Genomic Revolution(3.5449%)
since
2025/06/30
10.
ARK Genomic Revolution ETF(3.5072%)
since
2025/08/28
11.
Sumitomo Mitsui Trust Group Inc(3.1663%)
since
2025/06/30
12.
Amova Asset Management Americas, Inc(3.1623%)
since
2025/06/30
13.
Vanguard Total Stock Mkt Idx Inv(2.8255%)
since
2025/07/31
14.
Amova ARK Disruptive Innovation A USD(2.6861%)
since
2025/07/31
15.
iShares Russell 2000 ETF(2.2971%)
since
2025/08/31
16.
Geode Capital Management, LLC(2.2687%)
since
2025/06/30
17.
RIMA MANAGEMENT, LLC(2.0895%)
since
2025/06/30
18.
State Street Corp(1.9973%)
since
2025/06/30
19.
D. E. Shaw & Co LP(1.9573%)
since
2025/06/30
20.
Silvercrest Asset Management Group LLC(1.8185%)
since
2025/06/30
21.
Millennium Management LLC(1.5393%)
since
2025/06/30
22.
SILVERARC CAPITAL MANAGEMENT, LLC(1.298%)
since
2025/06/30
23.
IEQ CAPITAL, LLC(1.2615%)
since
2025/06/30
24.
AQR Capital Management LLC(1.1486%)
since
2025/06/30
25.
Goldman Sachs Group Inc(1.1012%)
since
2025/06/30
26.
Vanguard Institutional Extnd Mkt Idx Tr(1.0969%)
since
2025/07/31
27.
Morgan Stanley - Brokerage Accounts(1.0678%)
since
2025/06/30
28.
Fidelity Small Cap Index(0.9622%)
since
2025/06/30
29.
ING Investment Management LLC(0.8792%)
since
2025/06/30
30.
BlackRock Advantage Small Cap Core Instl(0.8741%)
since
2025/07/31
31.
iShares Russell 2000 Growth ETF(0.8398%)
since
2025/08/31
32.
Northern Trust Corp(0.8205%)
since
2025/06/30
33.
PRIMECAP Odyssey Aggressive Growth(0.6862%)
since
2025/06/30
34.
Silvercrest U.S. Small Cap Growth(0.5497%)
since
2025/06/30
35.
Fidelity Extended Market Index(0.5475%)
since
2025/07/31
36.
BlackRock Advantage Small Cap Gr Instl(0.4911%)
since
2025/07/31
37.
Schwab US Small-Cap ETFâ„¢(0.4861%)
since
2025/08/30
38.
Vanguard Russell 2000 ETF(0.4583%)
since
2025/07/31
39.
State St Russell Sm Cap® Indx SL Cl I(0.3381%)
since
2025/08/31
40.
Voya MI Dynamic Small Cap(0.322%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.